Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2013

View Archived Issues

Derma Sciences begins enrollment in phase III DSC-127 trial

CX3CR1 gene polymorphisms investigated in multiple sclerosis

DNA-binding protein SATB1 associated with aggressive prostate cancer

Merck & Co. prepares new BTK inhibitors

Abbott Laboratories presents novel CCR2 receptor antagonists

Spanish researchers disclose new DP2 receptor antagonists

MorphoSys divulges new bispecific monoclonal antibodies

Nihon University discloses novel apoptosis inducers

Novel DPP IV inhibitors synthesized at Boehringer Ingelheim

AstraZeneca patents new MCH1 receptor antagonists

Scientists at Janssen Pharmaceuticals present new gamma-secretase modulators

Avanir Pharmaceuticals reports interim data for AVP-786

Intellect Neurosciences begins preclinical proof-of-concept studies for TauC3

Bevacizumab improves survival in patients with cervical cancer

TGFR-1 inhibitor prevents metastasis in animal models of breast cancer

Gilead Sciences completes acquisition

Shire begins phase III study in epidermolysis bullosa

FDA issues draft guidance on developing drugs for early Alzheimer's disease

Data from phase II Reolysin trial in lung cancer reported

Glucokinase plus insulin genetic therapy cures diabetes in dogs

Phospho-p90RSK6 as a predictive marker in ER-positive breast cancer

EMA committee begins safety review of Diane-35 and generics

Bayer HealthCare to coordinate newly founded pan-European consortium

FDA approves second drug for multiple myeloma

RNL Bio seeks Korean clearance for phase II/III trials of stem cell product

Novo Nordisk receives complete response letter for Tresiba and Ryzodeg

Bayer HealthCare files applications for riociguat in U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...